These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 25993190)

  • 1. Triple-negative breast cancer: molecular subtypes and new targets for therapy.
    Lehmann BD; Pietenpol JA; Tan AR
    Am Soc Clin Oncol Educ Book; 2015; ():e31-9. PubMed ID: 25993190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple Negative Breast Cancer: A Tale of Two Decades.
    Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
    Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biology and Management of Patients With Triple-Negative Breast Cancer.
    Sharma P
    Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
    Sharma P
    Curr Treat Options Oncol; 2018 Apr; 19(5):22. PubMed ID: 29656345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions.
    Mai N; Abuhadra N; Jhaveri K
    Clin Breast Cancer; 2023 Dec; 23(8):784-799. PubMed ID: 37336650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.
    Diana A; Franzese E; Centonze S; Carlino F; Della Corte CM; Ventriglia J; Petrillo A; De Vita F; Alfano R; Ciardiello F; Orditura M
    Curr Oncol Rep; 2018 Aug; 20(10):76. PubMed ID: 30128845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.
    Lee A; Djamgoz MBA
    Cancer Treat Rev; 2018 Jan; 62():110-122. PubMed ID: 29202431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple negative breast cancer: new therapeutic approaches and BRCA status.
    Guney Eskiler G; Cecener G; Egeli U; Tunca B
    APMIS; 2018 May; 126(5):371-379. PubMed ID: 29696717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in Targeted Therapies for Triple-Negative Breast Cancer.
    McCann KE; Hurvitz SA; McAndrew N
    Drugs; 2019 Jul; 79(11):1217-1230. PubMed ID: 31254268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the androgen receptor in triple-negative breast cancer.
    Rampurwala M; Wisinski KB; O'Regan R
    Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
    Okuma HS; Yonemori K
    Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving management of metastatic triple negative breast cancer.
    Malhotra MK; Emens LA
    Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Therapies for Triple-Negative Breast Cancer.
    Lyons TG
    Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
    Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
    Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Therapeutic Strategies for Triple-Negative Breast Cancer.
    Székely B; Silber AL; Pusztai L
    Oncology (Williston Park); 2017 Feb; 31(2):130-7. PubMed ID: 28205193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted approaches to triple-negative breast cancer: current practice and future directions.
    Brunello A; Borgato L; Basso U; Lumachi F; Zagonel V
    Curr Med Chem; 2013; 20(5):605-12. PubMed ID: 23278396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-negative breast cancer and the potential for targeted therapy.
    Jhan JR; Andrechek ER
    Pharmacogenomics; 2017 Nov; 18(17):1595-1609. PubMed ID: 29095114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives.
    Fremd C; Jaeger D; Schneeweiss A
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):29-42. PubMed ID: 30351981
    [No Abstract]   [Full Text] [Related]  

  • 20. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
    Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
    Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.